



## **IowaBio Government Affairs Committee Advocacy Priorities**

**As established in its meeting on Monday, November 2, 2015**

In meeting of the IowaBio Government Affairs Committee, Advocacy Priorities for the coming year were established after discussion among the group members. The group met at 1:30 p.m. on Monday, November 2<sup>nd</sup> via conference call. The IowaBio Government Affairs Committee consists of the following members who participated in the call: Abby Gossman (Vertex), Chair; Joe Riley (Feed Energy Group); Billi Hunt (DuPont Pioneer); Frank Plescia (Boehringer Ingelheim); Jim DeMay (Pfizer); Mike St. Clair (Capitol Edge); Tom Fey (Capitol Edge); Chris Riley (ADM), Kate Kulesher Jarecke (Novartis), Melissa Moyer (IowaBio) and Joe Hrdlicka (IowaBio).

In its meeting, the Committee adopted these advocacy priorities in descending order of importance:

- IowaBio will continue to work with legislators, the Iowa Economic Development Authority (IEDA) and the Governor's Office toward favorable renewable biochemical tax credit legislation that provides incentives to the industry to contribute to added agricultural markets and additional opportunities for growth in Iowa's renewable/industrial sector.
- Efforts from the patient advocate and cures communities to encourage education and transparency efforts in enrolling patients in health care insurance plans is supported by IowaBio. Member companies providing innovative cures can better serve patients who are properly informed about their health care coverage.
- IowaBio's lobbyists and Government Affairs Committee will monitor and evaluate any legislation proposed in the areas of biosimilars, patent trolls, "right-to-try" or "experimental treatments", tiered drug pricing, Medicaid reform, GMO labeling and/or other areas for impact on the industry and make recommendations for appropriate positions.